Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...

Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...

Immunogenicity and transcriptomic biology in Nottingham histologic grade 3 breast cancer. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include a full ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...